Cytomx analysts
WebMar 20, 2024 · CytomX Therapeutics Price Performance. Shares of NASDAQ:CTMX opened at $1.86 on Monday. The company has a market capitalization of $122.91 million, a price-to-earnings ratio of -1.25 and a beta of ... WebApr 14, 2024 · CytomX Therapeutics, Inc. ( NASDAQ:CTMX – Get Rating) has been assigned a consensus recommendation of “Hold” from the twelve analysts that are …
Cytomx analysts
Did you know?
WebMar 29, 2024 · So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. Check out our latest analysis for CytomX Therapeutics . NasdaqGS:CTMX Earnings and Revenue Growth March 29th 2024 WebDXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security …
WebApr 6, 2024 · Find the latest CytomX Therapeutics, Inc. (CTMX) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. … WebApr 10, 2024 · CytomX Therapeutics presently has a consensus target price of $3.17, indicating a potential upside of 103.30%. Stoke Therapeutics has a consensus target price of $24.57, indicating a potential ...
WebMar 2, 2024 · InvestorsObserveris giving CytomX Therapeutics Inc (CTMX) an Analyst Rating Rank of 15, meaning CTMX is ranked higher by analysts than 15% of stocks. The average price target for CTMX is $3.564 and analyst’s rate the stock as a Buy. Wall Street analysts are rating CTMX a Buy today. WebMar 27, 2024 · CytomX Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2024, missing the Zacks Consensus...
WebOct 8, 2015 · Based in South San Francisco, CA, CytomX Therapeutics (NASDAQ: CTMX) scheduled a $97 million IPO on Nasdaq with a market capitalization of $524 million at a price range midpoint of $15 for ...
WebCytomX Therapeutics, Inc. (CTMX) Analyst Ratings, Estimates & Forecasts - Yahoo Finance U.S. markets open in 3 hours 21 minutes S&P Futures +19.25(+0.48%) Dow … raw paleo beef puppy medium 10kgsimple interest video 7th gradeWebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) has received an average rating of “Hold” from the twelve analysts that are covering the firm, Marketbeat … raw paleo cat adult beefWebCytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments. CytomX’s robust and differentiated pipeline ... simple interest spreadsheet excelWebJul 7, 2024 · Analysts have provided the following ratings for CytomX Therapeutics (NASDAQ:CTMX) within the last quarter: These 8 analysts have an average price target … raw paleo beefWebThe latest price target for CytomX Therapeutics ( NASDAQ: CTMX) was reported by Mizuho on Tuesday, March 28, 2024. The analyst firm set a price target for 2.00 expecting CTMX to rise to within 12 ... simple interest using function in cWebJan 5, 2024 · CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody ® technology platform, CytomX's goal is to transcend the limits of current cancer treatments. raw pack pressure canning pork